Summary The semisynthetic taxoid docetaxel was investigated in a phase 11 study in non-chemotherapy pretreated patients with metastatic urothelial cell cancer. Thirty patients (median age 61. range were treated with docetaxel 100 mg m-2 administered as a 1-h infusion every 3 weeks. Of 29 evaluable patients, four achieved a complete response and five a partial response, for an overall response rate of 3100. The median duration of response was 6 months (range 4-51+). A total of 104 cycles were administered. The median number of cycles given was three (range 1-9). Toxic effects of docetaxel mainly consisted of neutropenia, which, however, rarely caused infectious complications (5%). Fluid retention or neuropathy necessitated treatment cessation in two patients. We conclude that docetaxel is an effective agent in urothelial cell cancer, and should be further tested in combination chemotherapy.
Cisplatin and methotrexate are the txwo most commonlx used agents in the treatment of advanced transitional cancer of the urothelial tract (Roth. 1995 (Roth. . 1996 . In an attempt to improxe the results. Xarious combinations of cisplatin and methotrexate w-ith or wxithout other actix e agents such as x-inblastine and doxorubicin have been studied (Sternberg et al. 1989 : Roth. 1996 . Although xx ith combination chemotherapy response rates have increased to . the median duration of response and survial is still less than 1 x-ear. whereas such intensixe combination chemotherapy is at the cost of considerable toxicity. Apart from the limited actixvitv of these agents. intercurrent disease in this usuallv elderly patient population may preclude treatment wxith drugs such as cisplatin and methotrexate because of renal insufficiency. or doxorubicin because of cardiac disease. These factors warrant the search for new effective acgents. ex en in first-line treatment.
Docetaxel belongs to the taxoids and has demonstrated activitx in a x-ide xarietv of solid tumours. The administration schedule determined from phase I studies is 100 mu m-in a 1-h infusion ex erv 3 wxeeks. The dose-limiting toxicitx is neutropenia. We performed a phase II study wxith docetaxel in non-chemotherapypretreated patients with metastatic urothelial cell cancer.
PATIENTS AND METHODS

Patients
Eligibility criteria required histologically prox-en transitional cell carcinoma of the urinarx tract. measurable distant metastases or measurable pelvic tumour not amenable to local regional treatment. performance status (WAHO scale) 0-2. serum creatinine belowx 140 tmol 1-1. bilirubin belowx 1.25 x upper normal limit (UNL). aspartate-aminotransferase (AS.ATT belowx 2 x UN-L. or belowx 3 x UNL in case of proxen lixer metastases. neutrophils above 2 x 104 1-l and platelets aboxe 100 x 041-'. Patients with prior systemic chemotherapy. radiotherapy wxithin 4 weeks from protocol entry. irradiated indicator lesions or brain metastases. or xA ith poor medical risk wxere excluded.
Study design
Docetaxel (Taxotere. Rhone-Poulenc Rorer. Antony Cedex. France) x-as aiven at a dose of 100 ma m-'. even-3 weeks. Docetaxel as a concentrated solution in polysorbate 80 (Txxeen 80) wxas diluted in 250 ml of dextrose 5% and administered in a 1-h infusion. The dose was reduced by 25'k in case of neutrophils below-0.5 x 109 1-1 for more than 7 days. and/or complicated by fexver (> 38.5 C rectal temperature) requingn intraxenous antibiotics. and/or platelets below 25 x 104 1-. Treatment xas delayed for 1 week if neutrophils had not recoxered to aboxe 1.5 x 10 1-1. In case of cutaneous reactions grade 2 (NCI common toxicity criteria scale) or peripheral neuropathy grade 2. the dose was also reduced bx 25%/. Grade 3 non-haematological toxicitx resulted in postponement of the treatment until resolution to grade 0 or 1. after which treatment x as reinstituted. if medically appropriate. at a dose reduction of 25%. Othersxise. the patient xxas taken off study.
Prophylaxis for hypersensitixity reactions consisted of dexamethasone 10 ma orally at 24 and 6 h before and 24 h after the docetaxel infusion. and a single dose of clemastine 2 ma orally 30 min before the docetaxel infusion. After reports on its beneficial effects on the dexelopment of fluid retention and cutaneous toxicity. from the 24th patient onxxards in this studx. dexamethasone 8 mg, orally twice dailv wxas continued for a total of 4 day s after the administration of docetaxel. of bleedinc from a duodenal ulcer after the third cycle. At autopsy. there was a pathologically confirmed CR at all sites of disease. FiVe patients had a partial response. Of these five patients. in three the PRs could be confirmed at follow-up CT-scans. one patient had a PR after two cycles. but died of bowel perforation (due to diverticulitis coli. without concurrent neutropenia) follow ing the third cycle. and one patient had a more than 50%7 regression of liver metastases after the first cycle. but A as subsequently lost to followup. Sites of response were ly%mph node metastases (three). liver metastases (two). pelvic recurrence (one). The duration of confirmed partial responses was 4. 5 and 9 months. Thus. there were nine (3197) responses out of 29 evaluable patients. Two patients briefly had more than 50% regression observed after two cycles. but had progression after four cycles and. thus. only qualified for no changye. Another seven patients had no change after two (five patients) or four (two patients) cycles. and 11 patients had PD. Twelve patients w ere eventually crossed over to cisplatin-based chemotherapy. of whom four achieved PR. three had NC and five had PD. None of these four partial responders had initially responded to docetaxel. Conversely. of the three patients w ho had NC during docetaxel treatment and decided to cross over to cisplatin-based chemotherapy. none responded. Of the 13 patients who did not cross ouer to cisplatin-based chemotherapy. eight had refused a second line regimen. and five were inelioible because of clinical deterioration. performance status (two). or renal function impairment (three).
Toxicity
The most frequent toxicities are listed in Table 2 . The most frequent toxicity was neutropenia. which. however. w-as rapidly reversible: recoverv from nadir w as usually observed w ithin a few davs and never lasted more than 7 days. There were five episodes of neutropenic fever in a total of 104 cycles (5%7). 95 of w-hich were aiven at 100%c dose. and nine at 75% dose. Other frequent toxicities included myalgia and fatigue which were usually rrades 1 and 2 startinc on davs 3-5 after treatment and aradually (Yagoda. 1987 : Roth. 1995 : Roth. 1996 The nox-el pynrimidine antimetabolite 2emcitabine has been inxestigated for its single-agent actixity in four trials. including a total of 83 prex iously untreated patients and 27 pretreated patients showxing ox erall response rates of 29%-and 26%-respectixely (Pollera et al. 1994 : De Lena et al. 1996 : 'Moore et al. 1997 : Stadler et al. 1997 ).
Preclinical studies hax-e showxn the antiproliferatixe actixvit-of taxoids against human urothelial cancer cell lines and superioritx of these agents compared wxith classic microtubular inhibitors Niell et al. 1993 : DeHaxen et al. 1995 . In a phase II trial in 26 prexiously untreated patients. using a dose-intensixve schedule of paclitaxel (Taxol) at 250mc m-x with _ranubcvte colonv-stimulatin2 factor (G-CSF) support. an oxerall response rate of 42%-x-as reported. including an impressixe 27% CR rate. The median duration of response with paclitaxel at this dose xxas 11 months. In another phase II trial of paclitaxel given at a more conventional dose of 200 ma m-' in chemotherapy pretreated patients. only 1 out of 14 patients (79%) achieved a partial response (Papamichael et al. 1997) .
With the use of the semisynthetic taxoid docetaxel. in a phase II study in cisplatin-based chemotherapy pretreated patients. 4 out of 20 patients (20%7c) achieved a PR (McCaffrey et al. 1995) .
The present study is the first to report on the activity of docetaxel in previously untreated patients with urothelial cell cancer. In this unselected series of patients. several of whom had significant hepatic. pulmonary. and/or osseous metastases. who often do not benefit from chemotherapy. we obtained four complete ( 14%7) and five partial responses (171%7). for an overall response rate of 31 %7.
The median duration of response was 6 months. Docetaxel is. thus. an active agent in the treatment of urothelial cell cancer. The standard use of prolonged administration of dexamethasone from halfway through the study reduced fluid retention and skin toxicitv to infrequent and manageable side-effects. Mild or moderate sensorv neuropathy was frequently observed, but gradually developed and. as has been reported in the recent literature, severe and/or disabling neurotoxicity rarely occurred before a cumulative dose of docetaxel of 600 mg m-' (Hilkens et al. 1996) .
We have recently shown in a phase I study that the combination of docetaxel and cisplatin is feasible. at their common single-aaent doses (Pronk et al. 1997 
